FindTrial
Sign In

Comparing Simple Blood and Clinical Tests with a Specialized Liver Scan for Detecting Fatty Liver Disease in People with Metabolic Syndrome

TO Compare the Sensitivity and Specificity of the Fibrosis-4 Score and Fatty Liver Index with Controlled Attenuation Parameter in Estimating Liver Disease in Patients with Metabolic Syndrome - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112016
Enrollment
110
Registered
2026-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil

Sponsors

Sohan B C
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults (18 years to 60 years) diagnosed with metabolic syndrome. According to NCEP-ATP III criteria

Exclusion criteria

Exclusion criteria: Alcoholic liver disease(ascites), Viral hepatitis, Autoimmune liver disease, Familial lipid disorder, Chronic kidney disease

Design outcomes

Primary

MeasureTime frame
Compare the sensitivity and specificity of Fibrosis-4 score and Fatty Liver Index with Controlled Attenuation Parameter (FIBROSCAN)Timepoint: 52 weeks—

Secondary

MeasureTime frame
Evaluate the clinical utility of these indices in metabolic syndrome patients. Timepoint: 52 weeks—

Countries

India

Contacts

Public ContactSohan B C

KAHER Institute, Belagavi

wiseman2380@yahoo.com9738462380

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026